University of Texas Health Science Center at Houston

The Inner Circle Acknowledges, David R. Danly as a Distinguished Healthcare Professional for his contributions to the fields of Child and Adolescent Psychiatry

Retrieved on: 
Friday, October 13, 2023
Diagnosis, Bentham Science Publishers, University, European Child & Adolescent Psychiatry, University of Texas Health Science Center at Houston, Behavior, Psychiatry, Education, DSM-IV codes, Adolescence, Child and adolescent psychiatry, University of North Texas Health Science Center, Inner circle, Emotional and behavioral disorders, Patient, Cognition, Nursing, Child

TYLER, Texas, Oct. 13, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, David R. Danly is acknowledged as a Distinguished Healthcare Professional for his contributions to the fields of Child and Adolescent Psychiatry.

Key Points: 
  • TYLER, Texas, Oct. 13, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, David R. Danly is acknowledged as a Distinguished Healthcare Professional for his contributions to the fields of Child and Adolescent Psychiatry.
  • Dr. Danly pursued higher education at John P. and Katherine G. McGovern Medical School at UTHealth where he graduated in 1988.
  • He completed a residency in psychiatry in 1992 and a fellowship in child & adolescent psychiatry in 1994 at the University of Texas Health Science Center at Houston.
  • According to Dr. Danly, the center's mission is to provide and coordinate high-quality integrated healthcare services to the East Texas community to achieve independence and well-being.

University of Phoenix College of Doctoral Studies releases white paper exploring burnout as a cause for job dissatisfaction

Retrieved on: 
Saturday, August 12, 2023
Professional Services, Education, Business, Other Professional Services, Human Resources, University, Training, Burnout, Health administration, Emergency medicine, University of Texas System, DHA, Causality, Child protective services, Workplace, Teaching, McGovern Medical School, Marriage, Psychotherapy, MBA, Job satisfaction, Great Lakes University of Kisumu, Argosy University, University of Phoenix, Organization, Interface (computing), Business administration, Student, City, Tuberculosis, Doctor, Child, Barstow Community College, Phoenix College, University of Texas Health Science Center at Houston, Master of Business Administration, Health, Mental health, Nursing

University of Phoenix College of Doctoral Studies has released a new white paper, “Burnout as a Cause for Job Dissatisfaction,” a collaboration between authors Christa Banton, Ed.D., fellow in the University’s Center for Workplace Diversity and Inclusion Research (CWDIR) and Jose Garza, DHA, MBA, fellow, CWDIR.

Key Points: 
  • University of Phoenix College of Doctoral Studies has released a new white paper, “Burnout as a Cause for Job Dissatisfaction,” a collaboration between authors Christa Banton, Ed.D., fellow in the University’s Center for Workplace Diversity and Inclusion Research (CWDIR) and Jose Garza, DHA, MBA, fellow, CWDIR.
  • The white paper proposes that to address burnout, it is imperative to understand the facets of job satisfaction and create solutions to improve job satisfaction and overall burnout.
  • “Understanding the consequences of job dissatisfaction and tracking an organization’s level of work-life balance can provide an early indicator of intervention to improve job satisfaction, retention rates, and decrease overall burnout,” states Banton.
  • Garza completed his Doctorate in Health Administration with University of Phoenix and a Master of Business Administration with a concentration in healthcare management from Our Lady of the Lake University.

PaymentWorks Celebrates Business Milestones in the First Half of 2023

Retrieved on: 
Wednesday, July 26, 2023
St. Charles Health System, JPMorgan Chase, University of Texas Health Science Center at Houston, University, Roads of Strategic Importance, Investment, Catholic higher education, Florida State University, Controller, Health care, National Diaper Bank Network, Chubb, ACH, SDSU Research Foundation, Risk, Catholic University of America, Growth, Carahsoft, CPE, J. P. Morgan, Automation, Online shopping, Operation

BOSTON, July 26, 2023 (GLOBE NEWSWIRE) -- PaymentWorks, the digital supplier onboarding platform for secure, compliant and optimized business payments, concluded the first half of 2023 with several significant milestones.

Key Points: 
  • BOSTON, July 26, 2023 (GLOBE NEWSWIRE) -- PaymentWorks, the digital supplier onboarding platform for secure, compliant and optimized business payments, concluded the first half of 2023 with several significant milestones.
  • Customer Base Expansion: PaymentWorks customer base has grown rapidly and expanded into multiple industries, including:
    Higher Ed: PaymentWorks continues to be the digital supplier onboarding platform choice for colleges and universities.
  • New additions include: Florida State University, The Catholic University of America, and San Diego State University Research Foundation.
  • "The first half of 2023 solidified what we have always known: every organization of every size in every industry struggles with onboarding and managing vendor data," said Thayer Stewart, CEO of PaymentWorks.

Agios Announces Positive Results from Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease with Both Mitapivat Dose Arms Achieving Statistically Significant Hemoglobin Response

Retrieved on: 
Monday, June 26, 2023
Partnership, Hemolysis, University of Texas System, Aes, AGIO, Comparative oncology, Erythropoiesis, Report, Agios, Patient, Data, BID, University, Anemia, Host, RISE, Sickle cell disease, Agios Pharmaceuticals, Rare, Fatigue, Disease, Dentistry, Pharmaceutical industry, Copper, University of Texas Health Science Center at Houston

CAMBRIDGE, Mass., June 26, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the Phase 2 portion of the global RISE UP study of mitapivat in sickle cell disease met its primary endpoint of hemoglobin response for patients in both the 50 mg and 100 mg twice daily (BID) mitapivat arms. The safety profile for mitapivat observed in the study was generally consistent with previously reported data in other studies of sickle cell disease and other hemolytic anemias. Improvements were observed in markers of hemolysis and erythropoiesis and annualized rates of sickle cell pain crises at both mitapivat doses compared to placebo. These results support proceeding with the Phase 3 portion of the study.

Key Points: 
  • Improvements were observed in markers of hemolysis and erythropoiesis and annualized rates of sickle cell pain crises at both mitapivat doses compared to placebo.
  • “Sickle cell disease is a complex and debilitating disease characterized by anemia, pain crises, fatigue, cognitive effects and more.
  • Given the promising data for both mitapivat dose arms, the company will continue to analyze the study data over the coming weeks to select a dose for the Phase 3 study.
  • Agios plans to present a full analysis of the RISE UP Phase 2 data at an upcoming medical meeting.

Acasti Announces Appointment of New Scientific Advisory Board Members

Retrieved on: 
Thursday, June 22, 2023
AUC, McGovern Medical School, Calendar, Coronavirus Scientific Advisory Board, DRS, Doctor of Philosophy, Associate, Barrow Neurological Institute, Subarachnoid hemorrhage, Neurosurgery, Patient, Physician, Memorial Hermann–Texas Medical Center, Nimodipine, Neurology, University of Texas Health Science Center at Houston, Nursing care plan, FDA, Pharmaceutical industry, QC, MD

LAVAL, QC, June 22, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced the appointment of W. Taylor Kimberly, MD, PhD, Alejandro A. Rabinstein, MD and Sherry H-Y. Chou, MD to its Scientific Advisory Board.

Key Points: 
  • Chou, MD to its Scientific Advisory Board.
  • "We are extremely pleased to add eminent physicians with a deep understanding of aSAH and neurocritical care to the Acasti Scientific Advisory Board," commented Prashant Kohli, CEO of Acasti.
  • Kimberly, Rabinstein and Chou will offer unmatched insight into this indication."
  • "Acasti's Scientific Advisory Board now has a perfect blend of clinical expertise including neurosurgery and neurocritical care from the leading academic medical centers in the country," Kohli concluded.

Department of Defense Approves $4.9M for Next Phase Traumatic Brain Injury Study Using Hope Biosciences’ Stem Cells

Retrieved on: 
Thursday, June 1, 2023
Research, Contracts, Neurology, Clinical Trials, Health Technology, Stem Cells, Biotechnology, Health, Science, Defense, Critical care, Naval academy, Friends, George, McGovern Medical School, Clinical trial, Woman, TBI, Veteran, Microsoft Exchange Server, HB, Hope, MD, Traumatic brain injury, Pediatrics, Department of Defense Serum Repository, Transfusion medicine, University of Texas Health Science Center at Houston, Centers for Disease Control and Prevention, FDA, Conference, Safety, Complex, Nursing, Pharmaceutical industry, Trauma, Neuroscience

The award is a significant positive step toward developing treatment for a currently incurable condition that affects approximately 1.5 million Americans every year, killing 50,000 annually.

Key Points: 
  • The award is a significant positive step toward developing treatment for a currently incurable condition that affects approximately 1.5 million Americans every year, killing 50,000 annually.
  • Donna Chang, CEO of Hope Biosciences, highlighted the significance of their technology, stating, “Our repeatable stem cell therapy offers scalability, affordability and rapid delivery over one’s lifetime.
  • “Receipt of federal funding for research using Hope Biosciences’ stem cells is a deeply personal occasion,” reflects Jan Shultis, a Naval Academy graduate who joined the team at Hope Biosciences after thirteen years in uniform.
  • “TBI is part of my story, and that of scores of family members and friends who served.

Athersys Provides MultiStem Clinical Update

Retrieved on: 
Monday, January 9, 2023
Stem Cells, Biotechnology, Manufacturing, Health, Pharmaceutical, Other Science, Research, Other Manufacturing, Genetics, Science, Clinical Trials, Ischemia, Internet, EMA, McGovern Medical School, European Medicines Agency, University, Blood, Tissue, TPA, Mitsubishi, World Stroke Organization, Autoimmunity, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Regenerative medicine, Nature Reviews Neurology, Safety, University of Texas Health Science Center at Houston, FDA, Trauma, Inflammation, 3D, Department of Defense Serum Repository, Partnership, Houston Methodist Hospital, Conference, Protein, Central nervous system, FAHA, Resuscitation, Mitsubishi UFJ Financial Group, Weill Cornell Medicine, Food, Patient, Children's Memorial Hermann Hospital, State, Memorial Hermann–Texas Medical Center, Stroke, Trauma Center, Trauma center, MTEC, Pharmaceutical industry, Vaccine, Neurology

Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, today provided an update on ongoing clinical trials with MultiStem for the treatment of patients following hemorrhagic trauma (MATRICS-1) and for the treatment of ischemic stroke (MASTERS-2).

Key Points: 
  • Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, today provided an update on ongoing clinical trials with MultiStem for the treatment of patients following hemorrhagic trauma (MATRICS-1) and for the treatment of ischemic stroke (MASTERS-2).
  • MultiStem is a proprietary off-the-shelf stem cell product in late-stage clinical trials for acute ischemic stroke, as well as trauma and other inflammatory conditions.
  • MASTERS-2 is a company-sponsored Phase 3 randomized, double-blind, placebo-controlled trial evaluating MultiStem for the treatment of acute ischemic stroke.
  • Athersys’ enthusiasm about MultiStem for the treatment of ischemic stroke has been bolstered by results from completed clinical trials, and we look forward to providing updates on MASTERS-2 after we engage with regulatory authorities during the first quarter of 2023,” stated Dan Camardo, Chief Executive Officer of Athersys.

Big Sky Medical, Dallas-Based Healthcare Real Estate Investment Management Firm, Closes Third Investment in the Brazos Valley, Texas

Retrieved on: 
Friday, November 18, 2022
Texas A&M University System, Brazos Valley, GCC, Texas A&M Health Science Center, Science center, Texas A&M Health Science Center College of Medicine, Spine, Abu Dhabi Securities Exchange, University of Texas Health Science Center at Houston, Wealth management, Asset management, Commercial bank, Research, GFH, Dubai Financial Market, Real estate development, University system, Investment, Bahrain Bourse

DALLAS, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Big Sky Medical announces the closing of Texas A&M Health Science Center in Bryan, Texas.

Key Points: 
  • DALLAS, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Big Sky Medical announces the closing of Texas A&M Health Science Center in Bryan, Texas.
  • Oldham Goodwin has become an invaluable resource for Big Sky and our investments in Bryan, Texas, said Jason L. Signor, Founder and CEO of Big Sky Medical.
  • Big Sky Medical Real Estate is an investment manager focused on commercial real estate across the United States with an overweight focus on the medical office sector.
  • Big Sky was formed in 2020 by industry veteran Jason L. Signor to exclusively invest in healthcare and life science real estate.

New Study Finds 85% of Aneurysms Identified by Viz™ ANEURYSM had not Been Referred for Neurovascular Review

Retrieved on: 
Thursday, November 10, 2022
Technology, Medical Devices, Hospitals, Clinical Trials, Software, Health, General Health, Data Management, Artificial Intelligence, Hospital, Rupture, Multimedia, Aneurysm, Neurology, Diagnosis, Assistant, Viz, AI, Machine learning, McGovern Medical School, Disease, Patient, CTAS, Algorithm, Interventional Neuroradiology, University of Texas Health Science Center at Houston, Society, MD, Stroke, Medical imaging, Medical device

View the full release here: https://www.businesswire.com/news/home/20221110005419/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221110005419/en/
    Mobile viewer screen shots of Viz ANEURYSM.
  • Source: Viz.ai
    After screening nearly 1,200 computed tomography angiograms (CTAs) for stroke evaluation across eight stroke centers across Texas with Viz ANEURYSM, a total of 85% of the aneurysms detected by Viz ANEURYSM had not been previously referred for follow-up.
  • "This real-world clinical evidence validates the impact of Viz ANEURYSM in a large study.
  • For more information on the study results and Viz ANEURYSM, please join a webinar on Tuesday, November 29th at 6pm ET.

Nurse Practitioner Students at The University of Texas at Austin Receive National Honor for Lifesaving Efforts During Pandemic

Retrieved on: 
Friday, October 21, 2022
Kapu, Health policy, Vaccination, Vaccine, Education, Patient, Research, Program, Multimedia, Student, Partnership, History, University of Texas at Austin School of Information, NP, Practitioner, AANP, American Association, DNP, Association, Faculty, FAAN, APRN, Nurse practitioner, University of Texas Health Science Center at Houston, University, Austinite, NPS, University of Texas at Austin, COVID-19, View, Medicine, Pharmaceutical industry, Nursing

Students and faculty from UT Austin provided nearly 3,100 COVID-19 vaccines to the Austin community during the pandemic.

Key Points: 
  • Students and faculty from UT Austin provided nearly 3,100 COVID-19 vaccines to the Austin community during the pandemic.
  • "I applaud the incredible lifesaving work performed by UT Austin students and faculty during the public health care crisis," said Kapu, DNP, APRN, ACNP-BC, FAANP, FCCM, FAAN.
  • When it became clear the UT Austin vaccine clinic on campus would not be able to provide vaccinations to the entire community, faculty and students developed the VAMOS project.
  • The American Association of Nurse Practitioners (AANP) is the largest professional membership organization for nurse practitioners (NPs) of all specialties.